Next Article in Journal
Detection of miRNAs in urine of prostate cancer patients
Previous Article in Journal
Mean platelet volume and mean platelet volume/platelet count ratio in risk stratification of pulmonary embolism
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Association between the use of renin-angiotensin system blockers and development of in-hospital atrial fibrillation in patients with ST-segment elevation myocardial infarction

1
Department of Cardiology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey
2
Department of Family Medicine, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey
*
Author to whom correspondence should be addressed.
Medicina 2016, 52(2), 104-109; https://doi.org/10.1016/j.medici.2016.02.006
Received: 14 May 2015 / Revised: 19 February 2016 / Accepted: 29 February 2016 / Published: 11 March 2016
Background and aim: Atrial fibrillation (AF) is the most common supraventricular arrhythmia following ST-segment elevation myocardial infarction (STEMI). We evaluated the associa- tion between use of previous angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers (renin-angiotensin system [RAS] blockers) and started RAS blockers after MI and development of AF in patients presenting with acute STEMI.
Materials and methods: This retrospective study enrolled 1000 patients with acute STEMI who were admitted to the coronary care unit. Patients were divided into groups according to the use of RAS blockers before MI and development of AF rates was compared. Predictors of AF were determined by multiple logistic regression analysis.
Results: Of the 1000 patients presenting with STEMI, 247 received and 753 did not receive RAS blockers. The incidence of AF was 7.9%. The incidence of AF in patients receiving RAS blockers and did not receiving RAS blockers before MI were similar (5.7% vs. 8.6% respectively, P = 0.13). On the other hand, AF rate was lower in patients in whom RAS blockers were administered during MI as compared to those in whom these agents were not administered (7.2% vs. 28.6%, P < 0.001). Multiple regression analysis results showed that administration of RAS blockers or statins during hospitalization and left atrial diameter were associated with development of AF in patients with acute STEMI.
Conclusions: Previous therapy with RAS blockers does not reduce the incidence of AF in STEMI. Administration of RAS blockers at the hospital may decrease the AF rate in STEMI.
Keywords: Myocardial infarction; Atrial fibrillation; Renin-angiotensin system Myocardial infarction; Atrial fibrillation; Renin-angiotensin system
MDPI and ACS Style

Arslan, A.; Ozaydin, M.; Aksoy, F.; Arslan, B.; Bas, H.A.B.; Erdogan, D.; Varol, E.; Dogan, A. Association between the use of renin-angiotensin system blockers and development of in-hospital atrial fibrillation in patients with ST-segment elevation myocardial infarction. Medicina 2016, 52, 104-109.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Back to TopTop